Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/199942
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort

AutorLópez-Cortés, Luis F. CSIC ORCID; Almirante, Benito; Cuenca-Estrella, Manuel; Garnacho-Montero, José; Padilla, Belén; Puig-Asensio, M.; Ruiz-Camps, Isabel; Rodríguez-Baño, Jesús CSIC ORCID
Palabras claveBloodstream infections
Candidemia
Echinocandins
Empirical therapy
Targeted therapy
Fecha de publicaciónago-2016
EditorElsevier
CitaciónClinical Microbiology and Infection 22(8): 733.e1-733.e8 (2016)
ResumenWe compared the clinical efficacy of fluconazole and echinocandins in the treatment of candidemia in real practice. The CANDIPOP study is a prospective, population-based cohort study on candidemia carried out between May 2010 and April 2011 in 29 Spanish hospitals. Using strict inclusion criteria, we separately compared the impact of empirical and targeted therapy with fluconazole or echinocandins on 30-day mortality. Cox regression, including a propensity score (PS) for receiving echinocandins, stratified analysis on the PS quartiles and PS-based matched analyses, were performed. The empirical and targeted therapy cohorts comprised 316 and 421 cases, respectively; 30-day mortality was 18.7% with fluconazole and 33.9% with echinocandins (p 0.02) in the empirical therapy group and 19.8% with fluconazole and 27.7% with echinocandins (p 0.06) in the targeted therapy group. Multivariate Cox regression analysis including PS showed that empirical therapy with fluconazole was associated with better prognosis (adjusted hazard ratio 0.38; 95% confidence interval 0.17–0.81; p 0.01); no differences were found within each PS quartile or in cases matched according to PS. Targeted therapy with fluconazole did not show a significant association with mortality in the Cox regression analysis (adjusted hazard ratio 0.77; 95% confidence interval 0.41–1.46; p 0.63), in the PS quartiles or in PS-matched cases. The results were similar among patients with severe sepsis and septic shock. Empirical or targeted treatment with fluconazole was not associated with increased 30-day mortality compared to echinocandins among adults with candidemia.
DescripciónCANDIPOP Project from GEIH-GEMICOMED (SEIMC) and REIPI.
Versión del editorhttp://dx.doi.org/10.1016/j.cmi.2016.05.008
URIhttp://hdl.handle.net/10261/199942
DOI10.1016/j.cmi.2016.05.008
Identificadoresdoi: 10.1016/j.cmi.2016.05.008
issn: 1198-743X
e-issn: 1469-0691
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

SCOPUSTM   
Citations

34
checked on 13-mar-2024

WEB OF SCIENCETM
Citations

33
checked on 23-feb-2024

Page view(s)

230
checked on 18-mar-2024

Download(s)

20
checked on 18-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.